Although it has not embraced RNAi to the same degree as drug developers, agricultural biotech firms are increasingly interested in harnessing the gene-silencing technology to improve the yields of crop plants and to enhance their resistance to pests and environmental stressors, according to one industry insider.

Yet because of its relative nascence, ag-bio RNAi faces a number of challenges to its widespread application in the space, the greatest of which being what had long stymied the technology's use in human therapeutics — delivery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.